The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors.
Jeffrey R. Infante
No relevant relationships to disclose
Leena Gandhi
No relevant relationships to disclose
Geoffrey Shapiro
Research Funding - Sanofi
Howard A. Burris
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
José Baselga
Consultant or Advisory Role - Merck Serono; Sanofi
Karl Hsu
Employment or Leadership Position - Sanofi
Théa Faivre
Employment or Leadership Position - Merck Serono
Ekatherine Asatiani
Employment or Leadership Position - Merck Serono
Rebecca Suk Heist
No relevant relationships to disclose